Vitamin D metabolism and action in the prostate: Implications for health and disease

Molecular and Cellular Endocrinology

Volumn 347, Issue 1-2, 2011, Pages 61-69

  Swami, Srilatha ^a   Krishnan, Aruna V ^a   Feldman, David ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

1 Hydroxylase; 24 Hydroxylase; Calcitriol; Prostate cancer; Vitamin D; Vitamin D receptor (VDR)

Indexed keywords

25 HYDROXYCOLECALCIFEROL 24 HYDROXYLASE; 25 HYDROXYVITAMIN D3 24 HYDROXYLASE INHIBITOR; 5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; ANTINEOPLASTIC AGENT; CALCIDIOL 1 MONOOXYGENASE; CALCITRIOL; CALCITRIOL DERIVATIVE; CARBOPLATIN; CISPLATIN; COLECALCIFEROL; DEXAMETHASONE; DOCETAXEL; DOXERCALCIFEROL; GENISTEIN; ISOFLAVONE DERIVATIVE; KETOCONAZOLE; LIAROZOLE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGENASE; PACLITAXEL; PARICALCITOL; ROFECOXIB; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; BIOSYNTHESIS; CALCIUM METABOLISM; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; ENZYME ACTIVITY; HUMAN; HYPERCALCEMIA; NEPHROLITHIASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TARGET ORGAN; TISSUE DISTRIBUTION; UNSPECIFIED SIDE EFFECT; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CALCITRIOL; CHOLECALCIFEROL; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; ISOFLAVONES; MALE; MICE; PROSTATIC NEOPLASMS; RECEPTORS, CALCITRIOL; RISK FACTORS; STEROID HYDROXYLASES; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 82455208948     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.05.010     Document Type: Review

References (140)

1. Antman E.M., DeMets D., Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation 2005, 112(5):759-770.
2. Attia S., et al. Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin. Cancer Res. 2008, 14(8):2437-2443.
3. Banach-Petrosky W., et al. Vitamin D inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1;Pten mutant mice. Clin. Cancer Res. 2006, 12(19):5895-5901.
4. Bao B.Y., et al. Protective role of 1alpha,25-dihydroxyvitamin D3 against oxidative stress in nonmalignant human prostate epithelial cells. Int. J. Cancer 2008, 122(12):2699-2706.
5. Barboule N., et al. Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line. Oncogene 1997, 15(23):2867-2875.
6. Barreto A.M., et al. 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol. Biomarkers Prev. 2000, 9(3):265-270.
7. Beer T.M., Myrthue A. Calcitriol in cancer treatment: from the lab to the clinic. Mol. Cancer Ther. 2004, 3(3):373-381.
8. Beer T.M., Myrthue A. Calcitriol in the treatment of prostate cancer. Anticancer Res. 2006, 26(4A):2647-2651.
9. Beer T.M., et al. High-dose weekly oral calcitriol in patients with a rising PSA after prostatectomy or radiation for prostate carcinoma. Cancer 2003, 97(5):1217-1224.
10. Beer T.M., et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J. Clin. Oncol. 2007, 25(6):669-674.
11. Beer T.M., et al. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer 2008, 112(11):2377-2383.
12. Bell N.H., et al. Evidence for alteration of the vitamin D-endocrine system in blacks. J. Clin. Invest. 1985, 76(2):470-473.
13. Blagosklonny M.V., Dixon S.C., Figg W.D. Efficacy of microtubule-active drugs followed by ketoconazole in human metastatic prostate cancer cell lines. J. Urol. 2000, 163(3):1022-1026.
14. Blutt S.E., et al. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 2000, 141(1):10-17.
15. Bombardier C., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 2000, 343(21):1520-1528.
16. Chadha M.K., et al. Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer. Cancer 2010, 116(9):2132-2139.
17. Chen T.C., Holick M.F. Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol. Metab. 2003, 14(9):423-430.
18. Chen T.C., et al. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer. Clin. Cancer Res. 2000, 6(3):901-908.
19. Chen T.C., et al. Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. J. Cell. Biochem. 2003, 88(2):315-322.
20. Costa E.M., Hirst M.A., Feldman D. Regulation of 1,25-dihydroxyvitamin D3 receptors by vitamin D analogs in cultured mammalian cells. Endocrinology 1985, 117(5):2203-2210.
21. Davis J.N., Kucuk O., Sarkar F.H. Expression of prostate-specific antigen is transcriptionally regulated by genistein in prostate cancer cells. Mol. Carcinog. 2002, 34(2):91-101.
22. De Marzo A.M., et al. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am. J. Pathol. 1999, 155(6):1985-1992.
23. De Marzo A.M., et al. Inflammation in prostate carcinogenesis. Nat. Rev. Cancer 2007, 7(4):256-269.
24. Deeb K.K., Trump D.L., Johnson C.S. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat. Rev. Cancer 2007, 7(9):684-700.
25. Dwivedi P.P., et al. Identification of growth factor independent-1 (GFI1) as a repressor of 25-hydroxyvitamin D 1-alpha hydroxylase (CYP27B1) gene expression in human prostate cancer cells. Endocr. Relat. Cancer 2005, 12(2):351-365.
26. Dwivedi P.P., et al. Role of oncoprotein growth factor independent-1 (GFI1) in repression of 25-hydroxyvitamin D 1alpha-hydroxylase (CYP27B1): a comparative analysis in human prostate cancer and kidney cells. J. Steroid Biochem. Mol. Biol. 2007, 103(3-5):742-746.
27. Fang J., et al. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 2001, 58(3):411-416.
28. Farhan H., Wahala K., Cross H.S. Genistein inhibits Vitamin D hydroxylases CYP24 and CYP27B1 expression in prostate cells. J. Steroid Biochem. Mol. Biol. 2003, 84(4):423-429.
29. Feldman D. Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocr. Rev. 1986, 7(4):409-420.
30. Feldman D., Malloy P.J., Gross C. Vitamin D: biology, action and clinical implications. Osteoporosis 2001, 257-303. Academic Press, San Diego. R. Marcus (Ed.).
31. Flaig T.W., et al. A phase II trial of dexamethasone, vitamin D, and carboplatin in patients with hormone-refractory prostate cancer. Cancer 2006, 107(2):266-274.
32. Fleet J.C. Molecular actions of vitamin D contributing to cancer prevention. Mol. Aspects Med. 2008, 29(6):388-396.
33. Fowke J.H., et al. Association of nonsteroidal anti-inflammatory drugs, prostate specific antigen and prostate volume. J. Urol. 2009, 181(5):2064-2070.
34. Fritz W.A., et al. Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate. Mol. Cell. Endocrinol. 2002, 186(1):89-99.
35. Garland C.F., Garland F.C. Do sunlight and vitamin D reduce the likelihood of colon cancer?. Int. J. Epidemiol. 1980, 9(3):227-231.
36. Getzenberg R.H., et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 1997, 50(6):999-1006.
37. Gingrich J.R., et al. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res. 1997, 57(21):4687-4691.
38. Giovannucci E. Vitamin D and cancer incidence in the Harvard cohorts. Ann. Epidemiol. 2009, 19(2):84-88.
39. Gislason G.H., et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch. Intern. Med. 2009, 169(2):141-149.
40. Glass A.R., Eil C. Ketoconazole-induced reduction in serum 1,25-dihydroxyvitamin D. J. Clin. Endocrinol. Metab. 1986, 63(3):766-769.
41. Gombart A.F., Luong Q.T., Koeffler H.P. Vitamin D compounds: activity against microbes and cancer. Anticancer Res. 2006, 26(4A):2531-2542.
42. Graham D.J., et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005, 365(9458):475-481.
43. Gross C., et al. Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J. Urol. 1998, 159(6):2035-2039. discussion 2039-2040.
44. Gupta S., et al. Suppression of prostate carcinogenesis by dietary supplementation of celecoxib in transgenic adenocarcinoma of the mouse prostate model. Cancer Res. 2004, 64(9):3334-3343.
45. Hanchette C.L., Schwartz G.G. Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer 1992, 70(12):2861-2869.
46. Heaney R.P., et al. Vitamin D(3) is more potent than vitamin D(2) in humans. J. Clin. Endocrinol. Metab. 2011, 96(3):E447-E452.
47. Hempstock J., Kavanagh J.P., George N.J. Growth inhibition of prostate cell lines in vitro by phyto-oestrogens. Br. J. Urol. 1998, 82(4):560-563.
48. Hendrickson W.K., et al. Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J. Clin. Oncol. 2011, 29(17):2378-2385.
49. Hershberger P.A., et al. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin. Cancer Res. 2001, 7(4):1043-1051.
50. Hershberger P.A., et al. Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. Mol. Cancer Ther. 2002, 1(10):821-829.
51. Hewison M., Adams J.S. Extra-renal 1a-hydroxylate activity and human disease. Vitamin D 2005, 1379-1400. Elsevier, Academic Press, San Diego. D. Feldman (Ed.).
52. Hidalgo A.A., Trump D.L., Johnson C.S. Glucocorticoid regulation of the vitamin D receptor. J. Steroid Biochem. Mol. Biol. 2010, 121(1-2):372-375.
53. Hsu J.Y., et al. Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res. 2001, 61(7):2852-2856.
54. Jemal A., et al. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60. 10.3322/caac.20073.
55. Kahraman M., et al. Potent, selective and low-calcemic inhibitors of CYP24 hydroxylase: 24-sulfoximine analogues of the hormone 1alpha,25-dihydroxyvitamin D(3). J. Med. Chem. 2004, 47(27):6854-6863.
56. Kasper S., Smith J.A. Genetically modified mice and their use in developing therapeutic strategies for prostate cancer. J. Urol. 2004, 172(1):12-19.
57. Konety B.R., et al. Effect of prenatal vitamin D (calcitriol) exposure on the growth and development of the prostate. Prostate 1999, 41(3):181-189.
58. Konety B.R., et al. In vitro and in vivo effects of vitamin D (calcitriol) administration on the normal neonatal and prepubertal prostate. J. Urol. 2000, 164(5):1812-1818.
59. Kozlowski J.M., Grayhack J.T. Carcinoma of the prostate. Adult and Pediatric Urology 1995, 1575-1713. Mosby Year Book, St. Louis. J.Y. Gillenwater (Ed.).
60. Krill D., et al. Differential effects of vitamin D on normal human prostate epithelial and stromal cells in primary culture. Urology 1999, 54(1):171-177.
61. Krill D., et al. Expression patterns of vitamin D receptor in human prostate. J. Cell. Biochem. 2001, 82(4):566-572.
62. Krishnan A.V., Feldman D. Regulation of vitamin D receptor abundance. Vitamin D 1997, 179-200. Academic Press, San Diego. D. Feldman (Ed.).
63. Krishnan A.V., Feldman D. Anti-inflammatory activity of calcitriol that contributes to its therapeutic and chemopreventive effects in prostate cancer. Vitamin D: Physiology, Molecular Biology and Clinical Applications 2010, 1087-1104. Humana Press, Springer, New York. M.F. Holick (Ed.).
64. Krishnan A.V., Feldman D. Molecular pathways mediating the anti-inflammatory effects of calcitriol: implications for prostate cancer chemoprevention and treatment. Endocr. Relat. Cancer 2010, 17(1):R19-R38.
65. Krishnan A.V., Peehl D.M., Feldman D. Inhibition of prostate cancer growth by vitamin D: regulation of target gene expression. J. Cell. Biochem. 2003, 88(2):363-371.
66. Krishnan A.V., et al. Calcitriol as a chemopreventive and therapeutic agent in prostate cancer: role of anti-inflammatory activity. J. Bone Miner. Res. 2007, 22(Suppl. 2):V74-V80.
67. Krishnan A.V., Srinivas S., Feldman D. Inhibition of prostaglandin synthesis and actions contributes to the beneficial effects of calcitriol in prostate cancer. Dermatoendocrinology 2009, 1(1):7-11.
68. Krishnan A.V., et al. The role of vitamin D in cancer prevention and treatment. Endocrinol. Metab. Clin. North Am. 2010, 39(2):401-418.
69. Lechner D., et al. A 24-phenylsulfone analog of vitamin D inhibits 1alpha,25-dihydroxyvitamin D(3) degradation in vitamin D metabolism-competent cells. J. Pharmacol. Exp. Ther. 2007, 320(3):1119-1126.
70. Lehrer S., et al. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int. 2005, 95(7):961-962.
71. Loeb S., et al. Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old. Urology 2006, 67(2):316-320.
72. Loose D.S., et al. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J. Clin. Invest. 1983, 71(5):1495-1499.
73. Lucia M.S., et al. Workgroup I: rodent models of prostate cancer. Prostate 1998, 36(1):49-55.
74. Ly L.H., et al. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 1999, 140(5):2071-2076.
75. Ma J.F., et al. Mechanisms of decreased Vitamin D 1alpha-hydroxylase activity in prostate cancer cells. Mol. Cell. Endocrinol. 2004, 221(1-2):67-74.
76. Ma Y., et al. 1Alpha,25-dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model. Mol. Cancer Ther. 2008, 7(9):3047-3055.
77. Maggi M., et al. Pre-clinical evidence and clinical translation of benign prostatic hyperplasia treatment by the vitamin D receptor agonist BXL-628 (Elocalcitol). J. Endocrinol. Invest. 2006, 29(7):665-674.
78. Markowitz S.D., Bertagnolli M.M. Molecular origins of cancer: molecular basis of colorectal cancer. N. Engl. J. Med. 2009, 361(25):2449-2460.
79. McArdle P.A., et al. Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol. Int. 2006, 77(2):127-129.
80. McGuire T.F., Trump D.L., Johnson C.S. Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. J. Biol. Chem. 2001, 276(28):26365-26373.
81. Mentor-Marcel R., et al. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res. 2001, 61(18):6777-6782.
82. Miller G. Vitamin D and prostate cancer: biological interactions and clinical potentials. Cancer Metastasis Rev. 1999, 17353:360.
83. Miller G.J., et al. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1α,25-dihydroxyvitamin D3. Cancer Res. 1992, 52(3):515-520.
84. Miller G.J., et al. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1α,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines. Clin. Cancer Res. 1995, 1997:1003.
85. Mitchell J.H., Duthie S.J., Collins A.R. Effects of phytoestrogens on growth and DNA integrity in human prostate tumor cell lines: PC-3 and LNCaP. Nutr. Cancer 2000, 38(2):223-228.
86. Mizobuchi M., Towler D., Slatopolsky E. Vascular calcification: the killer of patients with chronic kidney disease. J. Am. Soc. Nephrol. 2009, 20(7):1453-1464.
87. Moffatt K.A., Johannes W.U., Miller G.J. 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clin. Cancer Res. 1999, 5(3):695-703.
88. Montironi R., et al. Karyometry detects subvisual differences in chromatin organization state between cribriform and flat high-grade prostatic intraepithelial neoplasia. Mod. Pathol. 2004, 17(8):928-937.
89. Moreno J., Krishnan A.V., Feldman D. Molecular mechanisms mediating the anti-proliferative effects of vitamin D in prostate cancer. J. Steroid Biochem. Mol. Biol. 2005, 97(1-2):31-36.
90. Moreno J., et al. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res. 2005, 65(17):7917-7925.
91. Morris M.J., et al. High-dose calcitriol, zoledronate, and dexamethasone for the treatment of progressive prostate carcinoma. Cancer 2004, 100(9):1868-1875.
92. Muindi J.R., et al. CYP24A1 inhibition enhances the antitumor activity of calcitriol. Endocrinology 2010, 151. 10.1210/en.2009-1156.
93. Narayanan N.K., et al. Inflammatory processes of prostate tissue microenvironment drive rat prostate carcinogenesis: preventive effects of celecoxib. Prostate 2009, 69(2):133-141.
94. Navone N.M., et al. Model systems of prostate cancer: uses and limitations. Cancer Metastasis Rev. 1998, 17(4):361-371.
95. Peehl D.M. Are primary cultures realistic models of prostate cancer?. J. Cell. Biochem. 2004, 91(1):185-195.
96. 3 on primary cultures of human prostatic cells. Cancer Res. 1994, 54(3):805-810.
97. Peehl D.M., et al. Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. J. Urol. 2002, 168(4, Pt. 1):1583-1588.
98. Peehl D.M., et al. Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J. Steroid Biochem. Mol. Biol. 2004, 92(3):131-141.
99. Peng X., et al. 25-Hydroxyvitamin D3 is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture. Breast Cancer Res. Treat. 2009, 113(1):31-41.
100. Petrioli R., et al. Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel. BJU Int. 2007, 100(4):775-779.
101. Pollard M., Wolter W. Prevention of spontaneous prostate-related cancer in Lobund-Wistar rats by a soy protein isolate/isoflavone diet. Prostate 2000, 45(2):101-105.
102. Rao A., et al. Genistein and vitamin D synergistically inhibit human prostatic epithelial cell growth. J. Nutr. 2002, 132(10):3191-3194.
103. Ray W.A., et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002, 360(9339):1071-1073.
104. Report, I., 2010. Dietary Reference Intakes for Calcium and Vitamin D. Institute of Medicine of the National Academies, November 2010. Available from: <>. http://www.iom.edu/vitamind.
105. Ruijter E., et al. Molecular genetics and epidemiology of prostate carcinoma. Endocr. Rev. 1999, 20(1):22-45.
106. Scher H.I., et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J. Clin. Oncol. 2011, 29(16):2191-2198.
107. Schwartz G.G., Hulka B.S. Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res. 1990, 10(5A):1307-1311.
108. Schwartz G.G., et al. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol. Biomarkers Prev. 1998, 7(5):391-395.
109. Schwartz G.G., et al. Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin. Cancer Res. 2005, 11(24, Pt. 1):8680-8685.
110. Severson R.K., et al. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. Cancer Res. 1989, 49(7):1857-1860.
111. Singer E.A., Palapattu G.S., van Wijngaarden E. Prostate-specific antigen levels in relation to consumption of nonsteroidal anti-inflammatory drugs and acetaminophen: results from the 2001-2002 National Health and Nutrition Examination Survey. Cancer 2008, 113(8):2053-2057.
112. Skinner H.G., Litzelman K., Schwartz G.G. Recent clinical trials of vitamin D3 supplementation and serum calcium levels in humans: implications for vitamin D-based chemoprevention. Curr. Opin. Investig. Drugs 2010, 11(6):678-687.
113. Skowronski R.J., Peehl D.M., Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993, 132(5):1952-1960.
114. Solomon S.D., et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006, 114(10):1028-1035.
115. Srinivas S., Feldman D. A phase II trial of calcitriol and naproxen in recurrent prostate cancer. Anticancer Res. 2009, 29(9):3605-3610.
116. Stamey T.A., et al. Localized prostate cancer. Cancer 1993, 71(Suppl.):933-938.
117. Stewart L.V., Weigel N.L. Vitamin D and prostate cancer. Exp. Biol. Med. (Maywood) 2004, 229(4):277-284.
118. Stewart Z.A., Mays D., Pietenpol J.A. Defective G1-S cell cycle checkpoint function sensitizes cells to microtubule inhibitor-induced apoptosis. Cancer Res. 1999, 59(15):3831-3837.
119. Steyerberg E.W., et al. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J. Urol. 2007, 177(1):107-112. discussion 112.
120. Studzinski G.P., Moore D.C. Sunlight - can it prevent as well as cause cancer?. Cancer Res. 1995, 55(18):4014-4022.
121. Swami S., et al. Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D(3) in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity. Mol. Cell. Endocrinol. 2005, 1212.
122. Swami S., et al. Calcitriol and genistein actions to inhibit the prostaglandin pathway: potential combination therapy to treat prostate cancer. J. Nutr. 2007, 137(1, Suppl.):205S-210S.
123. Swami S., et al. Inhibition of prostaglandin synthesis and actions by genistein in human prostate cancer cells and by soy isoflavones in prostate cancer patients. Int. J. Cancer 2009, 124(9):2050-2059.
124. Syed D.N., et al. Chemoprevention of prostate cancer through dietary agents: progress and promise. Cancer Epidemiol. Biomarkers Prev. 2007, 16(11):2193-2203.
125. Thorne J., Campbell M.J. The vitamin D receptor in cancer. Proc. Nutr. Soc. 2008, 67(2):115-127.
126. Ting H.J., et al. Docetaxel-induced growth inhibition and apoptosis in androgen independent prostate cancer cells are enhanced by 1alpha,25-dihydroxyvitamin D3. Cancer Lett. 2007, 247(1):122-129.
127. Townsend K., et al. Biological actions of extra-renal 25-hydroxyvitamin D-1alpha-hydroxylase and implications for chemoprevention and treatment. J. Steroid Biochem. Mol. Biol. 2005, 97(1-2):103-109.
128. Trump D.L., et al. Vitamin D compounds: clinical development as cancer therapy and prevention agents. Anticancer Res. 2006, 26(4A):2551-2556.
129. Trump D.L., et al. Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer 2006, 106(10):2136-2142.
130. Trump D.L., Deeb K.K., Johnson C.S. Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J. 2010, 16(1):1-9.
131. Turner A.G., et al. Regulation of the CYP27B1 5'-flanking region by transforming growth factor-beta in ROS 17/2.8 osteoblast-like cells. J. Steroid Biochem. Mol. Biol. 2007, 103(3-5):322-325.
132. van Weerden W.M., Romijn J.C. Use of nude mouse xenograft models in prostate cancer research. Prostate 2000, 43(4):263-271.
133. Wang W., Bergh A., Damber J.E. Increased expression of CCAAT/enhancer-binding protein beta in proliferative inflammatory atrophy of the prostate: relation with the expression of COX-2, the androgen receptor, and presence of focal chronic inflammation. Prostate 2007, 67(11):1238-1246.
134. Whitlatch L.W., et al. 25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J. Steroid Biochem. Mol. Biol. 2002, 81(2):135-140.
135. Whittemore A.S., et al. Prostate specific antigen levels in young adulthood predict prostate cancer risk: results from a cohort of Black and White Americans. J. Urol. 2005, 174(3):872-876. discussion 876.
136. Woo T.C., et al. Pilot study: potential role of vitamin D (cholecalciferol) in patients with PSA relapse after definitive therapy. Nutr. Cancer 2005, 51(1):32-36.
137. Yang E.S., Burnstein K.L. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J. Biol. Chem. 2003, 278(47):46862-46868.
138. Yee S.W., Campbell M.J., Simons C. Inhibition of vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells. J. Steroid Biochem. Mol. Biol. 2006, 98(4-5):228-235.
139. Young M.V., et al. The prostate 25-hydroxyvitamin D-1 alpha-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis 2004, 25(6):967-971.
140. Zha S., et al. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res. 2001, 61(24):8617-8623.